Our corporate partnerships
PVRI’s Roundtable
Our Roundtable is an alliance between industry and PVRI’s global network that allows us to work together to bring about meaningful change in the field of Pulmonary Vascular Disease (PVD) and ultimately to improve the quality and length of life for patients.
For our corporate partners in pharma and industry, the annual membership benefits include:
- access to our Innovative Drug Discovery Initiative’s multi-disciplinary global Workstreams and PVRI’s global leadership
- complementary delegate passes for our Annual Congress and our Drug Discovery & Development Symposium
- opportunities to exhibit and sponsor events at our meetings
- free PVRI memberships for members of your team
- opportunities to communicate with PVRI’s global member network*
- preferential data access rates
- sponsorship opportunities
Roundtable fees are based on the size of the corporate partner and their scale of operations in the PH marketplace. If you’d like to discuss joining our Roundtable, please contact our CEO Karen Osborn.
* An additional fee may be charged
Current Roundtable members
We’re delighted to be working with these Roundtable members this year – ranging from small pre-market companies to major global corporations. They bring energy and expertise to our network, and they share our passion for improving patients’ lives. We are grateful for their support.
Cereno Scientific is a pioneering biotech, developing innovative treatments for rare and common cardiovascular disease. Cereno’s lead drug candidate, CS1, is a HDAC inhibitor with epigenetic effects. A Phase II study, performed in collaboration with Abbott, is evaluating CS1’s safety, tolerability, and efficacy in patients with pulmonary arterial hypertension (PAH). Two initiatives performed during the ongoing Phase II study have shown positive findings suggesting potential clinical benefit of CS1. Since January 2024, the FDA´s Expanded Access Program enables patients with PAH to gain access to CS1 where no comparable alternative therapy options are available.
Cereno’s portfolio also comprises CS014, an HDAC inhibitor with epigenetic effects, being developed for thrombosis prevention, Phase I planned in Q2 2024, and CS585 a novel IP receptor agonist in preclinical development.
Cereno is a proud member of the PVRI Roundtable enabling us to collaborate to drive innovation of new treatments.
Fluidda is a pioneering innovator in the field of quantitative CT and has been working to revolutionize drug development and clinical research in pulmonary medicine for nearly 20 years. By directly and non-invasively analyzing the structure of the pulmonary vasculature, we aim to provide researchers and clinicians with more accurate tools to assess disease progression and individual response to therapy. We remain committed to facilitating the introduction of new and more effective therapies and management strategies for patients living pulmonary vascular disease.
At Johnson & Johnson, we continue to build on our decades-long commitment to the pulmonary hypertension community to transform the disease into a long-term manageable condition, so that patients can live a normal life. We want to reach more patients living with PAH earlier and support them in accessing best-in-class foundational oral therapies. We are continuously searching to advance the standard of care as well as finding new therapy options to complement our comprehensive portfolio which already covers the European Respiratory Society/European Society of Cardiology Guidelines.
Keros Therapeutics mission is to innovate therapies that have the potential to shift the treatment paradigm for a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (TGF-ß) family of proteins. KER-012, our lead product candidate in our pulmonary and cardiovascular franchise, is currently being developed for the treatment of pulmonary arterial hypertension. KER-012 is designed to normalize blood vessel thickness and heart function by inhibiting select TGF-β ligands, including activin A, activin B and myostatin (GDF8)—which stimulate smooth muscle hypertrophy and fibrosis—while sparing the bone morphogenic protein (BMP) ligands. For more information about TROPOS, our ongoing Phase 2 clinical trial in PAH, click here.
At MSD, innovation is at the heart of what we do. As a company, we are committed to the pursuit of transformative science that provides meaningful advancements for the patients we serve. A key area of focus for our company is cardiovascular and pulmonary diseases. We are focusing our efforts where the needs are greatest, and we feel we have the greatest opportunity to positively impact patients' lives, including heart failure, pulmonary hypertension, thrombosis, and atherosclerosis. We are driven by our pursuit to bring forth transformative medicines that have the potential to redefine the treatment landscape and improve patient care in these critical areas. In pulmonary hypertension, our efforts include multiple ongoing Phase 3 trials in pulmonary arterial hypertension and Phase 2 studies in other types of pulmonary hypertension. We look forward to continuing to work together with the research and patient community.
Pulmovant
Committed to transforming the lives of patients with pulmonary diseases.
United Therapeutics (UT) was founded in 1996 with a mission to save a daughter's life. In 2021, UT became the first publicly-traded biotech company to take the form of a public benefit corporation, with a purpose to develop novel pharmaceutical therapies and advance technologies that expand the availability of transplantable organs. United Therapeutics aligns its vision and mission, channeling enthusiasm, creativity, and persistence to innovate for patients' unmet medical needs. In the pulmonary hypertension (PH) space, United Therapeutics offers comprehensive support to patients through a diverse array of programs, educational materials, opportunities for clinical trials, advocacy endeavors, and partnerships with patient organizations. Through its partnership with PVRI, United Therapeutics aims to further advance research, treatment, and awareness in the fight against PH.
Our other corporate partners and supporters
Thank you to
- iOWNA: Enabling people to live longer, healthier lives for expert pro bono advice on the design of our Global Patient Survey
- United Therapeutics for gifting free PVRI memberships for PH doctors in low-income countries, and for sponsoring the wonderful celebratory Women’s Luncheon at our recent Annual Congress
- Statisticians for Society for matching us with a wonderful volunteer who’s busy crunching the data from our Patient Survey
Looking for other ways to support our work?
Make PVRI your charity of the year – a great way to focus charitable efforts and encourage your staff, customers and suppliers to work together. We can help you to organise a programme of fundraising activities and publicity to maximise your benefits.
Organise a fundraiser for the PVRI
Run, walk, hike, cycle or skydive for us. Hold a dinner, a dance, or a quiz for colleagues, family and friends.
Offer payroll giving
This is one of the easiest ways for people to donate regularly to the PVRI. Even small sums make a real difference, plus it’s flexible and tax efficient.
Corporate challenges and matched donations
Team fundraising is a fantastic way to encourage collaboration, networking and staff engagement. And if you match what your teams raise, they’ll love you for it – as will we!
For more information, please get in touch, or you can donate online.
